by The Welthi Bureau | 28 JULY 2018
Mumbai, Baltimore, 27th July 2018: Pharma major Lupin announced the launch of its Desoximetasone Topical Spray, 0.25%, having received an approval from the United States Food and Drug Administration (FDA) earlier.
Lupin’s Desoximetasone Topical Spray, 0.25% is the generic equivalent of Taro Pharmaceuticals U.S.A Inc.’s Topicort® Topical Spray, 0.25%. It is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.
Desoximetasone Topical Spray, 0.25% had annual sales of approximately USD 18.7 million in the US (IQVIA MAT May 2018).
Love Thyself - A Valentine's Day Message
7 Step Treatment For Spotless Skin
POWERFUL PROPERTIES OF THE HUMBLE BRINJAL
Neuberg Diagnostics & OptraSCAN® announce the ...
Keyhole Surgery: A revolution in malignant and ...
DELAY AGEING BY FASTING
World Stroke Day 29th Oct 2018
Hyderabad Doctors successfully perform Asia's ...
SuVitas Launches Bangalore’s First Dedicated ...
Itermittent Fasting: The How s and Why's
Our responsibility to our emotions
Eyes show you the world